Irritable bowel syndrome remains an incompletely understood, common syndrome with
significant unmet medical needs. In IBS patients, abdominal pain is a primary factor related
to quality of life impairment, symptom severity and health care utilization, and chronic
visceral hyperalgesia has been identified as an important aspect of IBS pathophysiology.
However, the development of therapies aimed at reducing this hyperalgesia (visceral
analgesics) has been only partially successful despite preclinical evidence supporting the …